The Berkeley‑linked biotech Radar Therapeutics has raised a total of $106.5 million to develop an all‑RNA platform that can stably insert therapeutic genetic material without using DNA or viral vectors.6
Radar describes its medicines as “jumping gene” RNA therapies, aiming to combine the programmability of RNA with the durable effects of gene insertion typically seen with DNA‑based or viral approaches.6
The company’s technology is positioned as a new class of programmable, targeted RNA therapies intended to be safer and more controllable than traditional gene therapies while still providing long‑lasting benefit.6
Radar Therapeutics is based in the Berkeley/San Francisco Bay Area ecosystem, drawing on regional expertise in RNA biology and genome engineering.6
The financing will be used to advance its RNA insertion platform toward the clinic, including building out preclinical pipelines and scaling manufacturing for all‑RNA therapeutics.6